Format

Send to:

Choose Destination
See comment in PubMed Commons below
Schizophr Bull. 2007 Sep;33(5):1120-30. Epub 2007 Jul 19.

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.

Author information

  • 1rwbuchanan@mprc.umaryland.edu

Abstract

Wayne Fenton was a major driving force behind the establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project mechanisms. These projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified 3 drug mechanisms of particular interest: cholinergic, dopaminergic, and glutamatergic. The TURNS project is designed to select potential cognitive-enhancing agents and evaluate their potential efficacy in the context of proof of concept or clinical efficacy trials. This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms.

PMID:
17641146
[PubMed - indexed for MEDLINE]
PMCID:
PMC2632365
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk